American Thoracic Society Selects Vasomune Therapeutics Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
AV-001 is a first-in-class drug candidate designed to fight disease by boosting vascular endothelial stability TORONTO, April 15, 2024, 2024 (BUSINESS WIRE) - Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company…